Randomized Controlled Trial Confirms That Antipsychotics Damage the Brain
A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.
Elderly Patients Who Stop Antipsychotics Have Better Outcomes
Older adults are often prescribed antipsychotics off-label for behavioral control in the hospital. But there’s no evidence for antipsychotics helping, and a great deal of evidence of harm.
Researchers: “We Do Not Suggest” Antipsychotics for Depression
Augmenting with antipsychotics was no better at reducing suicide than adding antidepressants, but led to increased risk of death from other causes.
Exploding Myths About Schizophrenia: An Interview with Courtenay Harding
The Vermont Longitudinal Study, led by Courtenay Harding, belied conventional beliefs about schizophrenia by showing remarkably good outcomes for patients discharged in the 1950s and '60s.
Recovery Rate Six Times Higher For Those Who Stop Antipsychotics Within Two Years
People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.
Antipsychotics Increase Risk of Dementia; New Research Illuminates Why
In JAMA psychiatry, researchers outline new theories connecting antipsychotic use in people with schizophrenia and increased dementia risk.
Do Antipsychotics Protect Against Early Death? A Review of the Evidence
Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.
A Short History of Tardive Dyskinesia: 65 Years of Drug-Induced Brain Damage That Rolls...
Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.
Deadly Prescriptions: New Study Links Antipsychotics to Life-Threatening Risks in Dementia Patients
With pharmaceutical companies pushing antipsychotics for off-label use, dementia patients are being put at risk for devastating health consequences. Research suggests safer alternatives exist—but why aren’t they being prioritized?
For People “At Risk for Psychosis,” Antipsychotics Associated with Worse Outcomes
Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.
Psychiatry Defends Its Antipsychotics: A Case Study of Institutional Corruption
Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.
Contribution of Antipsychotics to Suicidality and Depression
Peter Lehmann reviews the contribution of antipsychotics to suicide and depression in schizophrenia in the current International Journal of Psychotherapy. Publications about the intrinsic effects of...
Researchers Warn of “Brain Atrophy” in Children Prescribed Antipsychotics
Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.
Long-term Outcomes Better for Those Who Stop Taking Antipsychotics
Research undermines the prolonged use of antipsychotics in schizophrenia treatment, suggesting improved social functioning and quality of life with discontinuation.
The Charade of New Drug Approvals for Schizophrenia
The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.
Very Slow Taper Best for Antipsychotic Discontinuation
An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.
Antipsychotics Lead to Worse Outcomes in First-Episode Psychosis
Those who did not get antipsychotics in the first month were almost twice as likely to be in recovery after five years.
Greater Exposure to Antipsychotics Associated with Worse Long-Term Outcomes
A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.
Better Outcomes Off Medication for Those Recovered from First-Episode Schizophrenia
A new study has found that of 10 people who were fully recovered from their first episode of schizophrenia (FES), those not taking antipsychotics did better in terms of cognitive, social, and role functioning—and reached full recovery more quickly.
Largest Survey of Antipsychotic Experiences Reveals Negative Results
A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.
Adding Antipsychotics Worsens Outcomes in Psychotic Depression
Outcomes were worse for all, with young people on combination therapy twice as likely to experience rehospitalization or death by suicide than those on antidepressants alone.
The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive Dyskinesia
The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.
An FDA Whistleblower’s Documents: Commerce, Corruption, and Death
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
How Exercise Can Help With First Episode Psychosis
New study examines the experiences of people utilizing an exercise program following a first-episode psychosis.
The Case Against Antipsychotics
This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.
